NASDAQ:CALM

Cal-Maine Foods (NASDAQ: CALM) Price Target Adjusted Amid Profitability Concerns

Font: Financial Modeling Prep  • Oct 01, 2026

Market Chart
  • Analyst downgrades Cal-Maine Foods (NASDAQ: CALM) to "Hold" with a $70.00 price target, suggesting a 2.85% upside.
  • The company reported a significant net loss of $58.60 million and a 42% decline in net sales, primarily due to lower conventional egg prices.
  • Despite challenges, Cal-Maine Foods maintains a strong balance sheet and trades at an Enterprise Value-to-Sales (EV-to-Sales) ratio below 1x, with early signs of potential egg price normalization.

An analyst from Stephens recently adjusted the price target for Cal-Maine Foods (NASDAQ: CALM) to $70.00. Cal-Maine Foods is the largest producer and distributor of fresh shell eggs in the United States. At the time of the update, Cal-Maine Foods' stock was trading at $68.06 per share, meaning the new target suggests a potential upside of about 2.85%.

The company's stock rating was downgraded to "Hold" due to weaker-than-expected profitability. This weakness comes from a sharp decline in conventional egg prices. The company's operating leverage, where small changes in sales cause large changes in profit, highlights its sensitivity to these price cycles, as noted in an analysis by Seeking Alpha.

This financial pressure is clear in its first-quarter results. As highlighted by the Wall Street Journal, Cal-Maine reported a net loss of $58.60 million, a significant shift from a $199.30 million profit in the same period last year. Net sales also fell by 42% to $539.60 million, directly linked to lower egg prices.

Despite the downturn in the conventional egg sector, the company's specialty and prepared foods segments have shown more resilience. However, the conventional egg business posted a deeply negative margin, raising concerns about its operational efficiency. The company reported a quarterly Earnings Per Share (EPS) of -$1.26, which was below analyst expectations.

Even with these challenges, Cal-Maine maintains a strong balance sheet and continues its growth activities. There are early signs of egg price normalization, which could signal a future recovery. The company trades at an Enterprise Value-to-Sales (EV-to-Sales) ratio below 1x, which can suggest the stock is undervalued relative to its sales.

Market Overview
NIVF
NewGenIvf Group Limited
$0.13
27.72%
FNGR
FingerMotion, Inc.
$0.25
41.15%
AMOD
Alpha Modus Holdings, Inc.
$3.49
198.29%
FLUX
Flux Power Holdings, Inc.
$0.64
57.40%
SCNX
Scienture Holdings, Inc.
$0.16
-10.33%
SDEV
NovaBay Pharmaceuticals, Inc.
$7.48
104.37%
NKE
NIKE, Inc.
$33.87
-3.64%
NVDA
NVIDIA Corporation
$233.95
1.34%
QTEX
QTREX Quantum Ltd.
$1.10
40.20%
SPCX
Space Exploration Technologies Corp.
$158.96
7.35%